ProQR Therapeutics
PRQR
49 hedge funds and large institutions have $39.8M invested in ProQR Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 2 closing their positions.
404% more call options, than puts
Call options by funds: $454K | Put options by funds: $90K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
8% more capital invested
Capital invested by funds: $37M → $39.8M (+$2.82M)
4% more funds holding
Funds holding: 47 → 49 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.24% less ownership
Funds ownership: 22.76% → 21.51% (-1.2%)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$270K |
| 2 |
RA
RFG Advisory
Birmingham,
Alabama
|
+$68.4K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$68.1K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$52.9K |
| 5 |
Squarepoint
New York
|
+$52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
-$1.91M |
| 2 |
Millennium Management
New York
|
-$257K |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$205K |
| 4 |
MAM
Monaco Asset Management
Monaco
|
-$141K |
| 5 |
Morgan Stanley
New York
|
-$98.6K |
PRQR Hedge Fund Activity: Q1 2024 in Review
49 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2024, worth a combined $39.8M — up 7.6% from $37M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PRQR positions and 2 closed out — a net gain of 2 holders — while 10 added to existing stakes and 15 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $270K. The largest seller was M28 Capital Management, cutting an estimated $1.91M.
- 49 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2024, up from 47 in Q4 2023.
- Funds reported $39.8M of ProQR Therapeutics stock for Q1 2024, up 7.6% quarter-over-quarter.
- 4 funds opened new ProQR Therapeutics positions in Q1 2024 and 2 closed out, a net change of +2 holders.
- The largest ProQR Therapeutics buyer in Q1 2024 was Susquehanna International Group, an estimated $270K added.
- The largest ProQR Therapeutics seller in Q1 2024 was M28 Capital Management, an estimated $1.91M sold.
Based on aggregated 13F filings for Q1 2024.